Renalytix to Present at Stifel Healthcare Conference

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) will participate in the Stifel Healthcare Conference on November 15-16, 2022, at the Lotte New York Palace Hotel. Attendees can access a live and archived webcast of the presentation on the Company’s website starting at 3:35 p.m. ET on November 16. Renalytix is a pioneer in bioprognosis for kidney health, with its leading product, KidneyIntelX™, holding Breakthrough Designation from the FDA. This innovative solution aims to transform kidney disease prognosis and management.

NEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at https://investors.renalytix.com or via the webcast registration link below beginning at 3:35 p.m. Eastern Time on November 16, 2022.

Webcast registration link: https://wsw.com/webcast/stifel74/rnlx/2129288

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings		Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners		Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo

                                           

FAQ

What is the date of Renalytix's participation in the Stifel Healthcare Conference?

Renalytix will participate in the Stifel Healthcare Conference on November 15-16, 2022.

Where is the Stifel Healthcare Conference being held?

The Stifel Healthcare Conference will be held at the Lotte New York Palace Hotel.

What time will the Renalytix presentation be available on November 16, 2022?

The Renalytix presentation will be available starting at 3:35 p.m. Eastern Time on November 16, 2022.

How can I access the Renalytix presentation at the Stifel Conference?

You can access the Renalytix presentation live and archived on their website under the ‘Investors’ section.

What is KidneyIntelX™ and its significance?

KidneyIntelX™ is Renalytix's leading product designed for early-stage chronic kidney disease risk assessment, which has received Breakthrough Designation from the FDA.